Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes-Reference-Cited by-同舟云学术

Integrating comparative effectiveness design elements and endpoints into a phase III, randomized clinical trial (SWOG S1007) evaluating oncotypeDX-guided management for women with breast cancer involving lymph nodes

Published:2013-01 Issue:1 Volume:34 Page:1-9
ISSN:1551-7144
Container-title:Contemporary Clinical Trials
language:en
Short-container-title:Contemporary Clinical Trials

Author:

Ramsey Scott D.,Barlow William E.,Gonzalez-Angulo Ana M.,Tunis Sean,Baker Laurence,Crowley John,Deverka Patricia,Veenstra David,Hortobagyi Gabriel N.

Publisher

Elsevier BV

Subject

Pharmacology (medical),General Medicine

Reference22 articles.

1. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials;Lancet,2005

2. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial;Albain;Lancet Oncol,2010

3. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors;Tang;J Clin Oncol,2011

4. Anatomy and biology: two complementary sides of breast cancer prognostication;Pusztai;J Clin Oncol,2011

5. Comparative effectiveness research: a report from the Institute of Medicine;Sox;Ann Intern Med,2009

Cited by 78 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Addressing Social Determinants in the Era of Precision Medicine in Breast Cancer: Is It Sufficient to Reduce Disparities?;Cancer Epidemiology, Biomarkers & Prevention;2024-05-01

2. Molecular testing in breast cancer;Diagnostic Molecular Pathology;2024

3. Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer;Cancers;2023-09-07

4. Survey of clinicians on the use of adjuvant therapy for premenopausal women with breast cancer;PLOS ONE;2023-08-17

5. Cost-effectiveness analysis of the Oncotype DX Breast Recurrence Score test in node-positive early breast cancer;Journal of Medical Economics;2022-05-08